## BSX: Boston Scientific Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.91 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($88.14)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Boston Scientific transferring Galil Medical activity to Ireland**
- Source: Globes - Israel Business News | 20251211T180746 | Neutral | Relevance: 100%
- Boston Scientific is closing its Israeli subsidiary, Galil Medical, in Yokneâ€™am and transferring its cryoablation production activities to its central production site in Galway, Ireland. This move, which will be completed by 2028, is aimed at meeting expected demand for their interventional oncology products. While Galil Medical's approximately 100 employees will be affected, Boston Scientific emphasizes its continued investment and presence in Israel through other ventures.

**2. Boston Scientific announces positive coverage policy for Intracept procedure**
- Source: Med-Tech Insights | 20251211T135355 | Bullish | Relevance: 100%
- Boston Scientific announced that Health Care Service Corporation (HCSC), a major U.S. commercial health insurer, now covers the Intracept Procedure for eligible patients with chronic vertebrogenic low back pain. This policy, effective December 1, 2025, extends coverage to over 26 million people nationwide, acknowledging the clinical value and expanding access to this FDA-cleared, minimally invasive treatment. The Intracept Procedure is described as the only therapy specifically designed to target vertebrogenic pain with proven safety, effectiveness, and durability through long-term clinical studies.

**3. Boston Scientific Sustains Momentum in the PFA Market: What's Next?**
- Source: TradingView | 20251211T130808 | Bullish | Relevance: 100%
- Boston Scientific is maintaining a leading position in the Pulsed Field Ablation (PFA) market, particularly with its FARAPULSE technology, which continues to show strong adoption and positive clinical outcomes for treating atrial fibrillation. The company is actively investing in innovation to grow its market share in both AF and non-AF segments, while competitors like Abbott and Medtronic are also advancing their PFA and surgical robotic technologies. Despite a slight underperformance in stock price compared to the industry, Boston Scientific's earnings estimates are trending upwards, indicating a positive outlook.

**4. Can Boston Scientific (BSX) Sustain Its Momentum As Minimally Invasive Care Becomes Mainstream?**
- Source: Simply Wall Street | 20251211T030801 | Bullish | Relevance: 100%
- Boston Scientific has demonstrated strong growth with 23% revenue increase and tripled EPS over five years, driven by demand for its minimally invasive devices. The company is well-positioned due to aging populations and rising chronic diseases, with a narrative projecting $25.4 billion revenue and $4.8 billion earnings by 2028, suggesting a significant upside. However, potential risks include margin pressure from tariffs and regulatory setbacks.

**5. New insurance policy benefits Boston Scientific Intracept procedure**
- Source: MassDevice | 20251210T170144 | Bullish | Relevance: 100%
- Health Care Service Corporation (HCSC), a major commercial health insurer, has extended coverage to Boston Scientific's Intracept procedure for eligible patients with chronic vertebrogenic low back pain. This policy, effective December 1, 2025, significantly expands access to the minimally invasive, FDA-cleared procedure for over 26 million people nationwide. Boston Scientific acquired the Intracept technology through its 2023 acquisition of Relievant Medsystems and aims for category leadership in neuromodulation with this and upcoming product launches.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-21 | BTIG | $132 | $132 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-21 | BTIG | reit | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 3 ($1.31M) |
| Sells | 9 ($2.57M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Blackrock Inc.: 9.8% (-1.0%)
- Vanguard Group Inc: 9.3% (+0.8%)
- FMR, LLC: 6.7% (-8.2%)
- State Street Corpora: 4.4% (-0.4%)
- JPMORGAN CHASE & CO: 3.8% (+120.8%)

### Key Risks

1. Long-term trend broken: trading 8.5% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.91 indicates undervaluation relative to growth. Balance sheet: $2.6B free cash flow. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $137.2B |
| Beta | 0.67 |
| 52W Range | $85.98 - $109.50 |
| Short Interest | 1.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.91 |
| Forward P/E | 26.7 |
| Current P/E | 30.5 |
| YoY Growth | 14.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -7.9% to -5.6% (+2.3% in 5 days), confirming momentum buildup. Below STRENGTH zone by 9.6pp (needs >4.0% for momentum thesis). MRS_5 turning positive (1.3%) - potential reversal signal. AM_20 at -5.2% indicates price below own 20MA trend. Underperforming sector by 5.3pp, stock-specific weakness. Below SMA200 (0.92x), long-term trend not supportive. MACD histogram bearish (-0.83), momentum weakening. OFD pattern: +SBL (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -5.61% (CS: 5) | Weak |
| RSI_14 | 33.4 | Neutral |
| MACD Histogram | -0.83 | Bearish |
| vs SMA20 | 0.948x | Below |
| vs SMA50 | 0.937x | Below |
| vs SMA200 | 0.915x | Below |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $92.58
- **Stop Loss:** $88.14 (4.8% risk)
- **Target:** $101.46 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 225
- **Position Value:** $20,830.50
- **Portfolio %:** 20.83%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-04 (Est: $0.78)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.71 | $0.75 | +5.1% |
| 2025Q2 | $0.73 | $0.75 | +3.4% |
| 2025Q1 | $0.67 | $0.75 | +11.5% |
| 2024Q4 | $0.66 | $0.70 | +6.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*